LINE-1在肿瘤早期诊断和治疗中的研究与应用

doi:10.16288/j.yczz.21-062

[an error occurred while processing this directive]

Hereditas(Beijing) ›› 2021, Vol. 43 ›› Issue (6): 571-579.doi: 10.16288/j.yczz.21-062

• Review • Previous Articles Next Articles

Research and application on LINE-1 in diagnosis and treatment of tumorigenesis

Yanni Kou, Shan Cen(), Xiaoyu Li()

Department of Immunology, Institute of Medicinal Biotechnology, Chinese academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China

Received:2021-02-10 Revised:2021-05-07 Online:2021-06-20 Published:2021-05-28
Contact: Cen Shan,Li Xiaoyu E-mail:shancen@imb.pumc.edu.cn;xiaoyulik@hotmail.com
Supported by:
Supported by the National Science and Technology Major Project of the Ministry of Science and Technology of China No(2018ZX10301408-004);the National Natural Science Foundation of China No(31870164)

Abstract

Abstract:

Long interspersed element-1 (LINE-1), which is the only autonomous retrotransposon in human genome, makes up about 17% of the human genome. For LINE-1 retrotransposition may result in genome instability, it was strictly restricted by organisms, and its expression was therefore barely detected in normal somatic cells. However, the expression of LINE-1 is a common phenomenon in most tumor or cancer tissues, suggesting a close relationship between LINE-1 expression and cancer development. Differentially expressed LINE-1 in cancer tissues can be used as a biomarker for tumor diagnosis and an important indicator of prognosis after cancer therapeutics. Meanwhile, the feasibility of LINE-1 as a potential drug target for tumor treatment has also been evaluating and verifying in clinicals. In this review, we introduce the application of LINE-1 as a biomarker in tumor diagnosis and prognostic, as well as the research progress in LINE-1 as potential drug target for tumor treatment, in order to provide some references for clinical application in cancer treatment.

Key words: long interspersed element-1, tumor, diagnosis, treatment, prognosis

Yanni Kou, Shan Cen, Xiaoyu Li. Research and application on LINE-1 in diagnosis and treatment of tumorigenesis[J]. Hereditas(Beijing), 2021, 43(6): 571-579.

Figures/Tables 2

References 63

[1]	Burns KH. Transposable elements in cancer. Nat Rev Cancer, 2017,17(7):415-424.
[2]	Goodier JL, Kazazian HH. Retrotransposons revisited: the restraint and rehabilitation of parasites. Cell, 2008,135(1):23-35.
[3]	De Cecco M, Ito T, Petrashen AP, Elias AE, Skvir NJ, Criscione SW, Caligiana A, Brocculi G, Adney EM, Boeke JD, Le O, Beauséjour C, Ambati J, Ambati K, Simon M, Seluanov A, Gorbunova V, Slagboom PE, Helfand SL, Neretti N, Sedivy JM. L1 drives IFN in senescent cells and promotes age-associated inflammation. Nature, 2019,566(7742):73-78.
[4]	Hancks DC, Kazazian HH. Roles for retrotransposon insertions in human disease. Mob DNA, 2016,7:9.
[5]	Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell, 2011,144(5):646-674.
[6]	Liu Q, Wang JH, Li XY, Cen S. The connection between LINE-1 retrotransposition and human tumorigenesis. Hereditas(Beijing), 2016,38(2):93-102.
	刘茜, 王瑾晖, 李晓宇, 岑山. 逆转录转座子LINE-1与肿瘤的发生和发展. 遗传, 2016,38(2):93-102.
[7]	Zhang X, Zhang R, Yu JP. New understanding of the relevant role of LINE-1 retrotransposition in human disease and immune modulation. Front Cell Dev Biol, 2020,8:657.
[8]	Bodak M, Yu J, Ciaudo C. Regulation of LINE-1 in mammals. Biomol Concepts, 2014,5(5):409-428.
[9]	Deniz Ö, Frost JM, Branco MR. Regulation of transposable elements by DNA modifications. Nat Rev Genet, 2019,20(7):417-431.
[10]	Elbarbary RA, Lucas BA, Maquat LE. Retrotransposons as regulators of gene expression. Science, 2016, 351(6274): aac7247.
[11]	Terasaki N, Goodier JL, Cheung LE, Wang YJ, Kajikawa M, Kazazian HH, Okada N. In vitro screening for compounds that enhance human L1 mobilization. PLoS One, 2013,8(9):e74629.
[12]	Grundy EE, Diab N, Chiappinelli KB. Transposable element regulation and expression in cancer. FEBS J, 2021, doi: 10.1111/febs.15722.
[13]	Dolci M, Favero C, Toumi W, Favi E, Tarantini L, Signorini L, Basile G, Bollati V, D'Alessandro S, Bagnoli P, Ferrante P, Delbue S. Human endogenous retroviruses long terminal repeat methylation, transcription, and protein expression in human colon cancer. Front Oncol, 2020,10:569015.
[14]	Ko EJ, Oh YL, Kim HY, Eo WK, Kim H, Ock MS, Kim HS, Kim KH, Cha HJ. Correlation of long interspersed element-1 open reading frame 1 and c-Met proto-oncogene protein expression in ovarian cancer. Genes Genomics, 2019,41(11):1293-1299.
[15]	Daskalos A, Nikolaidis G, Xinarianos G, Savvari P, Cassidy A, Zakopoulou R, Kotsinas A, Gorgoulis V, Field JK, Liloglou T. Hypomethylation of retrotransposable elements correlates with genomic instability in non-small cell lung cancer. Int J Cancer, 2009,124(1):81-87.
[16]	Harada K, Baba Y, Ishimoto T, Chikamoto A, Kosumi K, Hayashi H, Nitta H, Hashimoto D, Beppu T, Baba H. LINE-1 methylation level and patient prognosis in a database of 208 hepatocellular carcinomas. Ann Surg Oncol, 2015,22(4):1280-1287.
[17]	Iwagami S, Baba Y, Watanabe M, Shigaki H, Miyake K, Ishimoto T, Iwatsuki M, Sakamaki K, Ohashi Y, Baba H. LINE-1 hypomethylation is associated with a poor prognosis among patients with curatively resected esophageal squamous cell carcinoma. Ann Surg, 2013,257(3):449-455.
[18]	van Hoesel AQ, van de Velde CJH, Kuppen PJK, Liefers GJ, Putter H, Sato Y, Elashoff DA, Turner RR, Shamonki JM, de Kruijf EM, van Nes JGH, Giuliano AE, Hoon DSB. Hypomethylation of LINE-1 in primary tumor has poor prognosis in young breast cancer patients: a retrospective cohort study. Breast Cancer Res Treat, 2012,134(3):1103-1114.
[19]	Weber B, Kimhi S, Howard G, Eden A, Lyko F. Demethylation of a LINE-1 antisense promoter in the cMet locus impairs Met signalling through induction of illegitimate transcription. Oncogene, 2010,29(43):5775-5784.
[20]	Wolff EM, Byun HM, Han HF, Sharma S, Nichols PW, Siegmund KD, Yang AS, Jones PA, Liang GN. Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer. PLoS Genet, 2010,6(4):e1000917.
[21]	Roman-Gomez J, Jimenez-Velasco A, Agirre X, Cervantes F, Sanchez J, Garate L, Barrios M, Castillejo JA, Navarro G, Colomer D, Prosper F, Heiniger A, Torres A. Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia. Oncogene, 2005,24(48):7213-7223.
[22]	Lin L, Wang ZW, Prescott MS, van Dekken H, Thomas DG, Giordano TJ, Chang AC, Orringer MB, Gruber SB, Moran JV, Glover TW, Beer DG. Multiple forms of genetic instability within a 2-Mb chromosomal segment of 3q26.3-q27 are associated with development of esophageal adenocarcinoma. Genes Chromosomes Cancer, 2006,45(4):319-331.
[23]	Miret N, Zappia CD, Altamirano G, Pontillo C, Zárate L, Gómez A, Lasagna M, Cocca C, Kass L, Monczor F, Randi A. AhR ligands reactivate LINE-1 retrotransposon in triple-negative breast cancer cells MDA-MB-231 and non-tumorigenic mammary epithelial cells NMuMG. Biochem Pharmacol, 2020,175:113904.
[24]	Tharp ME, Malki S, Bortvin A. Maximizing the ovarian reserve in mice by evading LINE-1 genotoxicity. Nat Commun, 2020,11(1):330.
[25]	Rodić N, Sharma R, Zampella J, Dai LX, Taylor MS, Hruban RH, Iacobuzio-Donahue CA, Maitra A, Torbenson MS, Goggins M, Shih IM, Duffield AS, Montgomery EA, Gabrielson E, Netto GJ, Lotan TL, De Marzo AM, Westra W, Binder ZA, Orr BA, Gallia GL, Eberhart CG, Boeke JD, Harris CR, Burns KH. Long interspersed element-1 protein expression is a hallmark of many human cancers. Am J Pathol, 2014,184(5):1280-1286.
[26]	Rodić N, Steranka JP, Makohon-Moore A, Moyer A, Shen PL, Sharma R, Kohutek ZA, Huang CR, Ahn D, Mita P, Taylor MS, Barker NJ, Hruban RH, Iacobuzio-Donahue CA, Boeke JD, Burns KH. Retrotransposon insertions in the clonal evolution of pancreatic ductal adenocarcinoma. Nat Med, 2015,21(9):1060-1064.
[27]	Doucet-O'Hare TT, Rodić N, Sharma R, Darbari I, Abril G, Choi JA, Young Ahn J, Cheng YL, Anders RA, Burns KH, Meltzer SJ, Kazazian HH. LINE-1 expression and retrotransposition in Barrett's esophagus and esophageal carcinoma. Proc Natl Acad Sci USA, 2015,112(35):E4894-E4900.
[28]	Papasotiriou I, Pantopikou K, Apostolou P. L1 retrotransposon expression in circulating tumor cells. PLoS One, 2017,12(2):e0171466.
[29]	Tristán-Ramos P, Rubio-Roldan A, Peris G, Sánchez L, Amador-Cubero S, Viollet S, Cristofari G, Heras SR. The tumor suppressor microRNA let-7 inhibits human LINE-1 retrotransposition. Nat Commun, 2020,11(1):5712.
[30]	De Luca C, Guadagni F, Sinibaldi-Vallebona P, Sentinelli S, Gallucci M, Hoffmann A, Schumann GG, Spadafora C, Sciamanna I. Enhanced expression of LINE-1-encoded ORF2 protein in early stages of colon and prostate transformation. Oncotarget, 2016,7(4):4048-4061.
[31]	Briggs EM, Spadafora C, Logan SK. A re-evaluation of LINE-1 ORF2 expression in LNCaP prostate cancer cells. Mob DNA, 2019,10:51.
[32]	Chiou PT, Ohms S, Board PG, Dahlstrom JE, Rangasamy D, Casarotto MG. Efavirenz as a potential drug for the treatment of triple-negative breast cancers. Clin Transl Oncol, 2021,23(2):353-363.
[33]	Shademan M, Zare K, Zahedi M, Mosannen Mozaffari H, Bagheri Hosseini H, Ghaffarzadegan K, Goshayeshi L, Dehghani H. Promoter methylation, transcription, and retrotransposition of LINE-1 in colorectal adenomas and adenocarcinomas. Cancer Cell Int, 2020,20:426.
[34]	Kerachian MA, Kerachian M. Long interspersed nucleotide element-1 (LINE-1) methylation in colorectal cancer. Clin Chim Acta, 2019,488:209-214.
[35]	Wang XY, Zhang Y, Yang N, Cheng H, Sun YJ. DNMT3a mediates paclitaxel-induced abnormal expression of LINE-1 by increasing the intragenic methylation. Hereditas (Beijing), 2020,42(1):100-111.
	王昕源, 张雨, 杨楠, 程禾, 孙玉洁. DNMT3a通过提升基因内部甲基化介导紫杉醇诱导的LINE-1异常表达. 遗传, 2020,42(1):100-111.
[36]	Chalitchagorn K, Shuangshoti S, Hourpai N, Kongruttanachok N, Tangkijvanich P, Thong-ngam D, Voravud N, Sriuranpong V, Mutirangura A. Distinctive pattern of LINE-1 methylation level in normal tissues and the association with carcinogenesis. Oncogene, 2004,23(54):8841-8846.
[37]	Belancio VP, Roy-Engel AM, Pochampally RR, Deininger P. Somatic expression of LINE-1 elements in human tissues. Nucleic Acids Res, 2010,38(12):3909-3922.
[38]	Pattamadilok J, Huapai N, Rattanatanyong P, Vasurattana A, Triratanachat S, Tresukosol D, Mutirangura A. LINE-1 hypomethylation level as a potential prognostic factor for epithelial ovarian cancer. Int J Gynecol Cancer, 2008,18(4):711-717.
[39]	Barchitta M, Quattrocchi A, Maugeri A, Vinciguerra M, Agodi A. LINE-1 hypomethylation in blood and tissue samples as an epigenetic marker for cancer risk: a systematic review and meta-analysis. PLoS One, 2014,9(10):e109478.
[40]	Rodić N, Sharma R, Sharma R, Zampella J, Dai LX, Taylor MS, Hruban RH, Iacobuzio-Donahue CA, Maitra A, Torbenson MS, Goggins M, Shih IM, Duffield AS, Montgomery EA, Gabrielson E, Netto GJ, Lotan TL, De Marzo AM, Westra W, Binder ZA, Orr BA, Gallia GL, Eberhart CG, Boeke JD, Harris CR, Burns KH. Long interspersed element-1 protein expression is a hallmark of many human cancers. Am J Pathol, 2014,184(5):1280-1286.
[41]	Lavasanifar A, Sharp CN, Korte EA, Yin T, Hosseinnejad K, Jortani SA. Long interspersed nuclear element-1 mobilization as a target in cancer diagnostics, prognostics and therapeutics. Clin Chim Acta, 2019,493:52-62.
[42]	Hosseinnejad K, Yin T, Gaskins JT, Bailen JL, Jortani SA. Discovery of the long interspersed nuclear element-1 activation product [open reading frame-1 (ORF1) protein] in human blood. Clin Chim Acta, 2018,487:228-232.
[43]	Gasior SL, Wakeman TP, Xu B, Deininger PL. The human LINE-1 retrotransposon creates DNA double-strand breaks. J Mol Biol, 2006,357(5):1383-1393.
[44]	Alisch RS, Garcia-Perez JL, Muotri AR, Gage FH, Moran JV. Unconventional translation of mammalian LINE-1 retrotransposons. Genes Dev, 2006,20(2):210-224.
[45]	Gualtieri A, Andreola F, Sciamanna I, Sinibaldi-Vallebona P, Serafino A, Spadafora C. Increased expression and copy number amplification of LINE-1 and SINE B1 retrotransposable elements in murine mammary carcinoma progression. Oncotarget, 2013,4(11):1882-1893.
[46]	Sciamanna I, De Luca C, Spadafora C. The reverse transcriptase encoded by LINE-1 retrotransposons in the genesis, progression, and therapy of cancer. Front Chem, 2016,4:6.
[47]	Sciamanna I, Landriscina M, Pittoggi C, Quirino M, Mearelli C, Beraldi R, Mattei E, Serafino A, Cassano A, Sinibaldi-Vallebona P, Garaci E, Barone C, Spadafora C. Inhibition of endogenous reverse transcriptase antagonizes human tumor growth. Oncogene, 2005,24(24):3923-3931.
[48]	Oricchio E, Sciamanna I, Beraldi R, Tolstonog GV, Schumann GG, Spadafora C. Distinct roles for LINE-1 and HERV-K retroelements in cell proliferation, differentiation and tumor progression. Oncogene, 2007,26(29):4226-4233.
[49]	Patnala R, Lee SH, Dahlstrom JE, Ohms S, Chen L, Dheen ST, Rangasamy D. Inhibition of LINE-1 retrotransposon- encoded reverse transcriptase modulates the expression of cell differentiation genes in breast cancer cells. Breast Cancer Res Treat, 2014,143(2):239-253.
[50]	Zhu YF, Feng F, Yu JY, Song B, Hu MM, Gao XD, Wang Y, Zhang Q. L1-ORF1p, a Smad4 interaction protein, promotes proliferation of HepG2 cells and tumorigenesis in mice. DNA Cell Biol, 2013,32(9):531-540.
[51]	Hur K, Cejas P, Feliu J, Moreno-Rubio J, Burgos E, Boland CR, Goel A. Hypomethylation of long interspersed nuclear element-1 (LINE-1) leads to activation of proto- oncogenes in human colorectal cancer metastasis. Gut, 2014,63(4):635-646.
[52]	Kuo KW, Sheu HM, Huang YS, Leung WC. Expression of transposon LINE-1 is relatively human-specific and function of the transcripts may be proliferation-essential. Biochem Biophys Res Commun, 1998,253(3):566-570.
[53]	Banuelos-Sanchez G, Sanchez L, Benitez-Guijarro M, Sanchez-Carnerero V, Salvador-Palomeque C, Tristan- Ramos P, Benkaddour-Boumzaouad M, Morell S, Garcia- Puche JL, Heras SR, Franco-Montalban F, Tamayo JA, Garcia-Perez JL. Synthesis and characterization of specific reverse transcriptase inhibitors for mammalian LINE-1 retrotransposons. Cell Chem Biol, 2019, 26(8): 1095-1109.e14.
[54]	Bellisai C, Sciamanna I, Rovella P, Giovannini D, Baranzini M, Pugliese GM, Zeya Ansari MS, Milite C, Sinibaldi-Vallebona P, Cirilli R, Sbardella G, Pichierri P, Trisciuoglio D, Lavia P, Serafino A, Spadafora C. Reverse transcriptase inhibitors promote the remodelling of nuclear architecture and induce autophagy in prostate cancer cells. Cancer lett, 2020,478:133-145.
[55]	Houédé N, Pulido M, Mourey L, Joly F, Ferrero JM, Bellera C, Priou F, Lalet C, Laroche-Clary A, Raffin MC, Ichas F, Puech A, Piazza PV. A phase II trial evaluating the efficacy and safety of efavirenz in metastatic castration- resistant prostate cancer. Oncologist, 2014,19(12):1227-1228.
[56]	Carlini F, Ridolfi B, Molinari A, Parisi C, Bozzuto G, Toccacieli L, Formisano G, De Orsi D, Paradisi S, Grober OMV, Ravo M, Weisz A, Arcieri R, Vella S, Gaudi S. The reverse transcription inhibitor abacavir shows anticancer activity in prostate cancer cell lines. PloS One, 2010,5(12):e14221.
[57]	Aschacher T, Sampl S, Käser L, Bernhard D, Spittler A, Holzmann K, Bergmann M. The combined use of known antiviral reverse transcriptase inhibitors AZT and DDI induce anticancer effects at low concentrations. Neoplasia, 2012,14(1):44-53.
[58]	Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Chan AT, Schernhammer ES, Giovannucci EL, Fuchs CS. A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J Natl Cancer Inst, 2008,100(23):1734-1738.
[59]	Zhu J, Ling Y, Xu Y, Lu MZ, Liu YP, Zhang CS. Elevated expression of MDR1 associated with Line-1 hypomethylation in esophageal squamous cell carcinoma. Int J Clin Exp Pathol, 2015,8(11):14392-14400.
[60]	Huang Y, Wei L, Sun AM, Zhao RC, Zhang J, Yang HT, Li B, Sun CJ, Ding XQ, Gao B, Zhong YQ, Qin Y. The evaluation value of methylation status of CpG island of SFRP1 and LINE1 gene promoter area in the prognosis of hepatocellular carcinom. J Sichuan Univ(Med Sci Ed), 2016,47(6):883-888.
	黄元, 魏玲, 孙爱民, 赵荣策, 张静, 杨含腾, 李波, 孙成均, 丁雪琴, 高波, 钟艳琴, 覃扬. SFRP1、LINE1基因启动子区CpG岛甲基化状态在肝细胞癌预后评估的价值. 四川大学学报(医学版). 2016,47(6):883-888.
[61]	Wang CH, Meng FK, Fei SY, Chen M, Zheng LJ. The clinical significance of retrotransposon expression in glioma. Chin J Lab Diag, 2020,24(8):1308-1310.
	王春辉, 孟繁凯, 费邵阳, 陈莫, 郑林杰. 逆转座子LINE-1在脑胶质瘤中异常活化的临床意义. 中国实验诊断学, 2020,24(8):1308-1310.
[62]	Harris CR, Normart R, Yang QF, Stevenson E, Haffty BG, Ganesan S, Cordon-Cardo C, Levine AJ, Tang LH. Association of nuclear localization of a long interspersed nuclear element-1 protein in breast tumors with poor prognostic outcomes. Genes Cancer, 2010,1(2):115-124.
[63]	Chen L, Dahlstrom JE, Chandra A, Board P, Rangasamy D. Prognostic value of LINE-1 retrotransposon expression and its subcellular localization in breast cancer. Breast Cancer Res Treat, 2012,136(1):129-142.

Metrics

Comments

www.chinagene.cn
备案号：京ICP备09063187号

LINE-1的异常表征	癌症实例	参考文献
LINE-1启动子低甲基化	结肠癌、卵巢癌、非小细胞肺癌、肝细胞癌、食管鳞状细胞癌、乳腺癌、急性髓性白血病、膀胱癌	[13~20]
LINE-1 RNA 表达	慢性粒细胞白血病、食管腺癌、乳腺癌、卵巢癌	[21~24]
ORF1p表达	乳腺癌、卵巢癌、胰腺癌、食道癌、结肠癌、肺癌、前列腺癌	[23~29]
ORF2p表达	结肠癌、前列腺癌、肺腺癌、乳腺浸润性导管癌	[29~32]

Research and application on LINE-1 in diagnosis and treatment of tumorigenesis

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 2

References 63

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Qingyu Sun, Yang Zhou, Lijuan Du, Mengke Zhang, Jiale Wang, Yuanyuan Ren, Fang Liu. Analysis between macrophage-related genes with prognosis and tumor microenvironment in non-small cell lung cancer [J]. Hereditas(Beijing), 2023, 45(8): 684-699.
[2]	Chenghao Yan, Weiyu Bai, Zhimeng Zhang, Junling Shen, Youjun Wang, Jianwei Sun. The roles and mechanism of STIM1 in tumorigenesis and metastasis [J]. Hereditas(Beijing), 2023, 45(5): 395-408.
[3]	Chunhui Ma, Haixu Hu, Lijuan Zhang, Yi Liu, Tianyi Liu. Establishment and verification of a digital PCR assay for the detection of CK19 expression in quantitative analysis of circulating tumor cell [J]. Hereditas(Beijing), 2023, 45(3): 250-260.
[4]	Dong Chang, Xiangxiang Liu, Rui Liu, Jianwei Sun. The role and regulatory mechanism of FSCN1 in breast tumorigenesis and progression [J]. Hereditas(Beijing), 2023, 45(2): 115-127.
[5]	Beiping Zeng, Hongen Xu, Lu Mao, Wenxue Tang. Molecular diagnosis of hereditary deafness and application of stepwise testing strategy [J]. Hereditas(Beijing), 2023, 45(1): 29-41.
[6]	Qinggang Hao, Fenggui Sun, Chenghao Yan, Jianwei Sun. Progress on the role and mechanism of MT1-MMP in tumor metastasis [J]. Hereditas(Beijing), 2022, 44(9): 745-755.
[7]	Yan Zhao, Chenxin Wang, Tianming Yang, Chunshuang Li, Lihong Zhang, Dongni Du, Ruoxi Wang, Jing Wang, Min Wei, Xueqing Ba. Linking oxidative DNA lesion 8-OxoG to tumor development and progression [J]. Hereditas(Beijing), 2022, 44(6): 466-477.
[8]	Tian Shu, Haochang Hu, Caijie Shen, Shaoyi Lin, Xiaomin Chen. Research progress of the correlation between genotype and phenotype in hypertrophic cardiomyopathy [J]. Hereditas(Beijing), 2022, 44(3): 198-207.
[9]	Min Shen, Yong Gu, Changjiang Ying, Mei Zhang, Tao Yang, Yang Chen. Diagnosis, treatment and genetic analysis of a case with fibrocalculous pancreatic diabetes [J]. Hereditas(Beijing), 2022, 44(11): 1079-1086.
[10]	Jiaqi Liang, Chang Liu, Wenxiang Zhang, Siyu Chen. Interaction between hepatokines and metabolic diseases [J]. Hereditas(Beijing), 2022, 44(10): 853-866.
[11]	Zhuo Wang, Xiaohan Shen, Qihui Shi. Advances in single-cell whole genome sequencing technology and its application in biomedicine [J]. Hereditas(Beijing), 2021, 43(2): 108-117.
[12]	Linan Zhao, Na Wang, Guoliang Yang, Xianbin Su, Zeguang Han. A method for reliable detection of genomic point mutations based on single-cell target-sequencing [J]. Hereditas(Beijing), 2020, 42(7): 703-712.
[13]	Shumin Chen, Ling Ma, Shan Cen. Progress of SLFN family proteins in tumor and virus infection [J]. Hereditas(Beijing), 2020, 42(5): 444-451.
[14]	Qiang Zhang, Mingliang Gu. Single-cell sequencing and its application in breast cancer [J]. Hereditas(Beijing), 2020, 42(3): 250-268.
[15]	Xiaoqi Zhao, Ying Ao, Haiyun Chen, Hui Wang. The role of miRNA in kidney development [J]. Hereditas(Beijing), 2020, 42(11): 1062-1072.